

Faecal microbiota composition associates with abdominal pain in the general population

We read with great interest the recent communication by Simrén *et al.*,¹ reporting a correlation between visceral hypersensitivity and GI symptom severity in functional GI disorders (FGID). Previously, it has been shown that visceral hypersensitivity can be modulated or even induced in animal models, by altering the composition of their gut microbiota with antibiotics or faecal transplantation from IBS donors.^{2,3} Hence, while a direct link between gut microbiota composition and visceral pain may need to be conclusively established, this holds great potential for translational exploitation in the treatment of IBS and other FGID. Thus far, the potential association between microbiota and abdominal pain in humans has only been investigated in one study that included 15 individuals.⁴ For this purpose, we studied 159 individuals (average age 59.1, 39.6% men) from the Swedish Population-based Colonoscopy (PopCol) cohort, previously described and with faecal microbiota 16S sequencing data and daily recordings of abdominal pain (number of episodes, duration and intensity) collected over the same period (7.41 ± 7.91 days).⁵⁻⁷ Among these, 52 individuals (assigned to the case group)




Figure 1 Faecal microbiota β -diversity associates with abdominal pain. Top: Heat map of Spearman correlation between pain indices and faecal microbiota β -diversity, based on principal coordinate analysis applied to Bray-Curtis and Jaccard matrices at the level of genera (Genera) and operational taxonomic units with 97% sequence similarity (OTU 97%). The first three principal coordinates (PC) are reported (PC1, PC2 and PC3) and significant correlations (false discovery rate < 0.1) are highlighted by a black frame. Bottom: Box plots of PC scores in cases and controls, where significant differences (corrected p value < 0.05) are highlighted with *.

reported at least one episode of light, moderate or intense pain (respective scores 1, 2 and 3), while the other 107 (controls) never reported pain. On average, those with pain experienced it 0.30 times per day (range 0.07–1.57), for 2.46 hours each time (range 0.37–9) and on a light-moderate intensity level of 1.39 per episode (range 1–2.1). When compared, both at the level of genus and species-level operational taxonomic units (OTU), β -diversity measures of faecal microbiota from cases and controls significantly differed (figure 1). In addition, significant correlations with microbiota β -diversity were detected for pain indices of frequency, duration and intensity (figure 1). Classifying individuals according to their microbiota profiles clustered into

enterotypes (<http://enterotyping.embl.de>) resulted in three groups, respectively, enriched for *unclassified Ruminococcaceae*, *Prevotella* and *Bacteroides*. As shown in figure 2, a χ^2 analysis revealed their distribution to be significantly different in cases and controls ($p=0.039$), and the *Prevotella*-predominant enterotype was underrepresented in the pain group (21% vs 41% in controls). When taxa previously associated with abdominal symptoms in animal models and clinical studies (*Bacteroides*, *unclassified Ruminococcaceae*, *Butyrivibrio*, *Prevotella*, *Faecalibacterium*, *Streptococcus*, *Bifidobacterium*, *Blautia*, *Akkermansia*, *Lactobacillus*, *Alisipites* and *Enterobacter*) were compared with a Wilcoxon rank-sum test for their




Figure 2 Faecal microbiota enterotype distribution differs in individuals with abdominal pain compared with controls. Principal component analysis (left) and relative distribution (right) of enterotypes according to the presence (case) or absence (control) of abdominal pain. Participants were classified into three enterotypes primarily characterised by *unclassified Ruminococcaceae*, *Prevotella* or *Bacteroides*. * $p < 0.05$.

abundance in the pain and control groups, Benjamini-Hochberg corrected significant differences were observed for *Prevotella* (decreased in cases, $p=0.038$), *Blautia* (increased in cases, $p=0.045$), *Streptococcus* (increased in cases, $p=0.038$) and *Lactobacillus* (increased in cases, $p=0.038$). In particular, in an indicator value analysis on genus level, *Prevotella* could significantly predict the absence of abdominal pain (corrected $p=0.016$, association statistics=0.76 using the *multipatt* function of the R package *indicspecies*). Similar results were obtained when testing correlations with pain frequency, duration and intensity and after removal of individuals ($n=18$) whose questionnaire data were compatible with a diagnosis of IBS according to Rome III criteria (not shown).

Our results provide novel evidence linking faecal microbiota composition to the occurrence of abdominal pain and its frequency, duration and intensity in the general population. The negative association of *Prevotella* with pain parallels observations previously made in IBS studies where the *Prevotella*-predominant enterotype was shown to be less common among patients.⁸ The information we report at the general population level may contribute to translational opportunities for the identification and treatment of individuals at risk of IBS and other FGIDs and warrants further studies in independent populations.

Fatemeh Hadizadeh,^{1,2} Ferdinando Bonfiglio,^{1,3} Meriem Belheouane,^{4,5} Marie Vallier,^{4,5} Sascha Sauer,⁶ Corinna Bang,⁷ Luis Bujanda,^{3,8} Anna Andreasson,^{9,10} Lars Agréus,⁹ Lars Engstrand,^{11,12} Nicholas J Talley,^{9,13,14,15} Joseph Rafter,¹ John F Baines,^{4,5} Susanna Walter,¹⁶ Andre Franke,⁷ Mauro D'Amato^{3,17,18}

¹Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

²Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

³Department of Gastrointestinal and Liver Diseases, BioDonostia Health Research Institute, San Sebastian, Spain

⁴Institute of Experimental Medicine, Christian-Albrechts-University of Kiel, Kiel, Germany

⁵Evolutionary Genomics, Max Planck Institute for Evolutionary Biology, Plön, Germany

⁶Max Delbrück Center for Molecular Medicine (BIMSB/BIH), Berlin, Germany

⁷Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany

⁸Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco UPV/EHU, San Sebastián, Spain

⁹Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

¹⁰Stress Research Institute, Stockholm University, Stockholm, Sweden

¹¹Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

¹²Clinical Genomics Facility, Science for Life Laboratory, Solna, Sweden

¹³Faculty of Health and Medicine, University of Newcastle, Newcastle, Australia

¹⁴Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, USA

¹⁵Australian GI Research Alliance (AGIRA), Australia

¹⁶Division of Gastroenterology, Institution of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

¹⁷Department of Medicine, Unit of Clinical Epidemiology, Karolinska Institutet, Stockholm, Sweden

¹⁸KERBASQUE, Basque Science Foundation, Bilbao, Spain

Correspondence to Professor Mauro D'Amato, Gastrointestinal Genetics Unit, BioDonostia HRI, Paseo Dr Beguiristain s/n, 20014 San Sebastian, Spain; mauro.damato@ki.se

Contributors MDA had the original idea and designed the study together with FH. SW, ANA, LE, NJT and LA collected material, characterised the study subjects and acquired data. AF, JB, CB and SS performed microbiota sequencing. FH, FB, MB, MV, LB, JR and MDA did the data analysis and interpretation. FH and MDA drafted the manuscript with critical revision from all authors.

Funding Supported by funds from the Swedish Research Council ("Vetenskapsrådet") to MD and the European Union Seventh Framework Program (FP7/2007-2013, grant number 262055, ES-GI) to MD, SS and AF; Iranian ministry of health and medical education to FH; FH is a member of the Research Training Group (RTG) 1743 "Genes, Environment and Inflammation", funded by German Research Foundation (DFG).

Competing interests None declared.

Patient consent None.

Ethics approval Karolinska Institute.

Provenance and peer review Not commissioned; internally peer reviewed.



OPEN ACCESS

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.



To cite Hadizadeh F, Bonfiglio F, Belheouane M, *et al.* *Gut* 2018;**67**:778–779.

Received 4 July 2017

Accepted 13 July 2017

Published Online First 1 August 2017

Gut 2018;**67**:778–779. doi:10.1136/gutjnl-2017-314792

REFERENCES

- 1 Simrén M, Törnblom H, Palsson OS, *et al.* Visceral hypersensitivity is associated with GI symptom severity

in functional GI disorders: consistent findings from five different patient cohorts. *Gut* 2018;**67**:255–62.

- 2 Aguilera M, Vergara P, Martínez V. Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice. *Neurogastroenterol Motil* 2013;**25**:e515–e529.
- 3 Crouzet L, Gaultier E, Del'Homme C, *et al.* The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. *Neurogastroenterol Motil* 2013;**25**:e272–e282.
- 4 Jalanka-Tuovinen J, Salonen A, Nikkilä J, *et al.* Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. *PLoS One* 2011;**6**:e23035.
- 5 Kjellström L, Molinder H, Agréus L, *et al.* A randomly selected population sample undergoing colonoscopy: prevalence of the irritable bowel syndrome and the impact of selection factors. *Eur J Gastroenterol Hepatol* 2014;**26**:268–75.
- 6 Hadizadeh F, Walter S, Belheouane M, *et al.* Stool frequency is associated with gut microbiota composition. *Gut* 2017;**66**:559–60.
- 7 Walter SA, Kjellström L, Nyhlin H, *et al.* Assessment of normal bowel habits in the general adult population: the Popcol study. *Scand J Gastroenterol* 2010;**45**:556–66.
- 8 Tap J, Derrien M, Törnblom H, *et al.* Identification of an intestinal microbiota signature associated with Severity of irritable bowel syndrome. *Gastroenterology* 2017;**152**:111–23.